|
gptkbp:instanceOf
|
gptkb:drug
antiplatelet drug
|
|
gptkbp:approvalYear
|
2009
|
|
gptkbp:approvedBy
|
gptkb:FDA
|
|
gptkbp:associatedWith
|
gptkb:ticagrelor
gptkb:clopidogrel
gptkb:ticlopidine
|
|
gptkbp:ATCCode
|
B01AC22
|
|
gptkbp:bioavailability
|
79%
|
|
gptkbp:brand
|
Effient
Efient
|
|
gptkbp:CASNumber
|
389574-19-0
|
|
gptkbp:category
|
prodrug
thienopyridine
|
|
gptkbp:chemicalFormula
|
C20H20FNO3S
|
|
gptkbp:contraindication
|
active pathological bleeding
history of stroke
history of transient ischemic attack
|
|
gptkbp:developedBy
|
gptkb:Eli_Lilly_and_Company
gptkb:Daiichi_Sankyo
|
|
gptkbp:eliminationHalfLife
|
7 hours
|
|
gptkbp:excretion
|
urine
feces
|
|
gptkbp:firstMarketedYear
|
2010
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
prasugrel
|
|
gptkbp:legalStatus
|
prescription only
patented
|
|
gptkbp:marketedAs
|
gptkb:Japan
|
|
gptkbp:mechanismOfAction
|
P2Y12 receptor inhibitor
|
|
gptkbp:metabolism
|
liver
active thiol metabolite
|
|
gptkbp:molecularWeight
|
373.44 g/mol
|
|
gptkbp:pregnancyCategory
|
C (US)
B3 (Australia)
|
|
gptkbp:proteinBinding
|
98%
|
|
gptkbp:PubChem_CID
|
6918213
|
|
gptkbp:riskFactor
|
increased bleeding risk in patients over 75 years
not recommended in patients with body weight <60 kg
not recommended in patients with history of stroke or TIA
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
gptkb:anemia
bleeding
rash
|
|
gptkbp:synonym
|
CS-747
prasugrel hydrochloride
|
|
gptkbp:UNII
|
85M03CNU4M
|
|
gptkbp:usedFor
|
gptkb:acute_coronary_syndrome
prevention of thrombotic cardiovascular events
|
|
gptkbp:bfsParent
|
gptkb:CYP3A4
|
|
gptkbp:bfsLayer
|
5
|